Switch to
Place Order
Glenmark Pharmaceuticals Ltd
GLENMARK
Health CarePharmaceuticals
SmallcapWith a market cap of ₹17,439 cr, stock is ranked 258
Moderate RiskStock is 2.44x as volatile as Nifty
631.502.18% (+13.45)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
Health CarePharmaceuticals
SmallcapWith a market cap of ₹17,439 cr, stock is ranked 258
Moderate RiskStock is 2.44x as volatile as Nifty
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 58.68 | 1.85 | 0.40% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 34.23 | 4.59 | 0.82% |
Forecast & RatingsDetailed Forecast
35%
Analysts have suggested that investors can buy this stock
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Sun Pharmaceutical Industries Ltd
FY PE Ratio
28.40
1Y Return
17.91%
Buy Reco %
97.37
Cipla Ltd
FY PE Ratio
28.06
1Y Return
0.41%
Buy Reco %
70.00
Dr Reddy's Laboratories Ltd
FY PE Ratio
16.97
1Y Return
7.69%
Buy Reco %
55.00
Torrent Pharmaceuticals Ltd
FY PE Ratio
48.26
1Y Return
28.58%
Buy Reco %
70.97
Mankind Pharma Ltd
FY PE Ratio
44.50
1Y Return
0.00%
Buy Reco %
100.00
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Revenue
Profit
All values in ₹ Thousand cr.
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Buy Glenmark Pharmaceuticals, target price Rs 619.8: ICICI Direct
4 days ago•Economic Times
Glenmark Pharmaceuticals joins Science Based Target Initiative
6 days ago•Free Press Journal
Neutral Glenmark Pharma; target of Rs 580: Motilal Oswal
1 week ago•Moneycontrol
Recent EventsAll events
Updates
Annual Secretarial Compliance Report
Cash Dividend
Final • Div/Share: ₹ 2.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant